Brief: Tarsus Pharmaceuticals Q1 Operating Expenses USD 65.298 Million
08/05/2024 21:05
May 08 (Reuters) - Tarsus Pharmaceuticals Q1 basic EPS USD -1.01. * Q1 net income USD -35.731 million vs. IBES estimate USD -39.2 million
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)